Rapid Micro Biosystems (RPID)
(Delayed Data from NSDQ)
$0.90 USD
+0.01 (1.37%)
Updated Oct 4, 2024 12:45 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
Income Statements
Fiscal Year end for Rapid Micro Biosystems, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 23 | 17 | 23 | 16 | 17 |
Cost Of Goods | 28 | 26 | 31 | 24 | 17 |
Gross Profit | -5 | -9 | -8 | -8 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 51 | 55 | 39 | 22 | 18 |
Income After Depreciation & Amortization | -57 | -63 | -47 | -31 | -19 |
Non-Operating Income | 4 | 0 | -24 | -3 | 0 |
Interest Expense | 0 | -2 | 3 | 3 | 2 |
Pretax Income | -52 | -61 | -73 | -37 | -21 |
Income Taxes | 0 | -1 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -52 | -61 | -74 | -37 | -21 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -52 | -61 | -74 | -37 | -21 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -53 | -60 | -46 | -29 | -17 |
Depreciation & Amortization (Cash Flow) | 3 | 3 | 2 | 2 | 1 |
Income After Depreciation & Amortization | -57 | -63 | -47 | -31 | -19 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 43.02 | 42.45 | 19.78 | NA | NA |
Diluted EPS Before Non-Recurring Items | -1.22 | -1.43 | -2.79 | NA | NA |
Diluted Net EPS (GAAP) | -1.22 | -1.43 | -3.94 | -126.11 | NA |
Fiscal Year end for Rapid Micro Biosystems, Inc falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | 6.62 | 5.61 | 6.34 | 6.15 | 5.00 |
Cost Of Goods | 6.81 | 7.13 | 6.51 | 7.78 | 6.89 |
Gross Profit | -0.19 | -1.52 | -0.17 | -1.63 | -1.89 |
SG&A, R&D, and Dept/Amort Expenses | 13.19 | 12.75 | 12.02 | 12.82 | 13.16 |
Income After SG&A, R&D, and Dept/Amort Expenses | -13.38 | -14.27 | -12.19 | -14.45 | -15.05 |
Non-Operating Income | 0.82 | 0.95 | 1.02 | 1.07 | 1.04 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -12.56 | -13.32 | -11.16 | -13.38 | -14.01 |
Income Taxes | 0.02 | 0.00 | 0.01 | 0.01 | 0.01 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -12.58 | -13.32 | -11.17 | -13.39 | -14.02 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -12.58 | -13.32 | -11.17 | -13.39 | -14.02 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | 43.62 | 43.25 | 43.14 | 43.08 | 43.06 |
Diluted EPS Before Non-Recurring Items | -0.29 | -0.31 | -0.26 | -0.31 | -0.33 |
Diluted Net EPS (GAAP) | -0.29 | -0.31 | -0.26 | -0.31 | -0.33 |